MOTS-C: The Mitochondrial Peptide Under FDA Review for Obesity and Osteoporosis
Regulatory Update (April 2026): MOTS-C is one of seven peptides scheduled for FDA Pharmacy Compounding Advisory Committee review on July 23, 2026. The committee will evaluate MOTS-C for obesity and osteoporosis and consider it for the Section 503A Bulk Drug Substances List. Read our full coverage: FDA to Review 7 Peptides for Compounding List in July 2026.
MOTS-C is unusual in the peptide world. Most therapeutic peptides come from genes in the nucleus. MOTS-C is encoded inside mitochondrial DNA, making it one of the first identified mitochondrial-derived peptides. Researchers have studied it for roles in energy metabolism, insulin sensitivity, exercise performance, and bone health. The FDA is now reviewing MOTS-C for the Section 503A Bulk Drug Substances List in July 2026, with obesity and osteoporosis as the specific uses under evaluation.
Interested in peptide therapy? Find vetted peptide therapy clinics near you.
| Topic | Detail |
|---|---|
| What it is | 16-amino-acid peptide encoded within mitochondrial DNA |
| Full name | Mitochondrial Open Reading Frame of the 12S rRNA type-C |
| Research focus | Obesity, insulin resistance, osteoporosis, exercise adaptation, aging |
| Mechanism | Activates AMPK signaling, improves glucose uptake, enhances mitochondrial function |
| Administration | Subcutaneous injection |
| FDA status | Not approved; under PCAC review July 23, 2026 for 503A Bulks List inclusion |
What Is MOTS-C?
MOTS-C stands for Mitochondrial Open Reading Frame of the 12S rRNA type-C. It is a 16-amino-acid peptide encoded within the mitochondrial genome itself, not the nuclear DNA like most proteins. That location matters. Mitochondria are the energy centers of the cell, and peptides produced inside them tend to play central roles in metabolism, aging, and cellular stress response. MOTS-C was discovered in 2015 and has been one of the most studied mitochondrial-derived peptides since.
How MOTS-C Works
The mechanism centers on a cellular energy sensor called AMP-activated protein kinase, or AMPK. When energy is low or metabolic stress is high, AMPK activates pathways that improve glucose uptake, burn fat, and support mitochondrial health. Exercise and caloric restriction both activate AMPK. MOTS-C appears to activate AMPK directly, essentially mimicking some of the metabolic effects of exercise at the cellular level. Research published in Cell Metabolism first characterized this mechanism.
Research on Obesity and Insulin Resistance
Obesity is one of the two uses the FDA is reviewing. In animal studies, MOTS-C injections reduced weight gain on high-fat diets, improved insulin sensitivity, and lowered fasting blood glucose. The effects were similar to what is seen with increased exercise. Human studies are much more limited but early data has shown improvements in metabolic markers in insulin-resistant patients. MOTS-C levels naturally decline with age and in some metabolic diseases, which is part of why researchers have explored supplementation as a therapeutic strategy.
MOTS-C and Bone Health
Osteoporosis is the second indication under FDA review. Bone tissue turns over constantly through the balance of osteoblast activity (bone building) and osteoclast activity (bone breakdown). Mitochondrial function plays a larger role in this balance than most people realize. Studies have shown that MOTS-C supports osteoblast activity while limiting excessive osteoclast-driven bone loss. In animal models of age-related bone loss, MOTS-C treatment preserved bone density. Human data is still early but the biological plausibility is strong.
MOTS-C and Exercise
Exercise researchers have shown that MOTS-C levels rise in response to physical activity. That observation led to interest in whether supplementation could enhance exercise adaptation. Animal studies have shown improved endurance, better recovery, and favorable changes in muscle fiber composition after MOTS-C administration. Athletes and biohackers have driven some of the off-label clinical demand for the peptide. The World Anti-Doping Agency has not yet taken formal action on MOTS-C, though that status could change as more research emerges.
Administration and Dosing
MOTS-C is administered by subcutaneous injection. There is no oral form that maintains activity. Dosing protocols vary depending on the indication and patient goals. Clinics typically use injection schedules ranging from a few times per week to daily during loading phases. Any protocol should be supervised by a licensed physician who can monitor metabolic markers and adjust as needed.
Safety Profile
MOTS-C appears well tolerated in the research published so far. Reported side effects include mild injection site reactions, occasional fatigue, and transient changes in appetite. Because MOTS-C influences insulin sensitivity and glucose metabolism, patients with diabetes require close monitoring to avoid hypoglycemia. The long-term safety profile in humans has not been fully characterized, which is typical for peptides in the pre-approval stage.
Regulatory and Cost Considerations
MOTS-C has no FDA approval for any indication. The July 2026 PCAC review will determine whether it can be legally compounded under Section 503A. Cash-pay costs at compounding pharmacies typically run $200 to $500 per month at common therapeutic doses. Insurance coverage is not available. Patients considering MOTS-C should work with a clinic that uses a USP 797 compliant compounding pharmacy and orders appropriate metabolic labs before and during therapy.
Finding a Clinic
Peptide therapy for metabolic or bone health should always involve comprehensive lab work and ongoing clinical monitoring. Our peptide therapy directory lists verified clinics across the country. For context on where MOTS-C fits into the broader peptide landscape, see our complete guide to peptide treatments.
